Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -29.58% is 55% above its 5-year average of -66.41%, near the high end of its 5-year range (-125.64%–-24.17%).
14.40% below its 12-month average of -25.86%.
Reported quarterly EBITDA margin; no daily interpolation. Q3 FY2026 (2026-06-30): -24.92%.
EBITDA MARGIN
-29.58%
EBITDA MARGIN AVG TTM
-25.86%
EBITDA MARGIN AVG 3Y
-40.51%
EBITDA MARGIN AVG 5Y
-66.41%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-14.40%
CURRENT VS 3Y AVG
+26.98%
CURRENT VS 5Y AVG
+55.46%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Twist Bioscience Corporation
Market Cap
$10.72B
EBITDA Margin
-29.58%
TTM Avg
-25.86%
3Y Avg
-40.51%
5Y Avg
-66.41%
Market Cap
$10.69B
EBITDA Margin
15.05%
TTM Avg
14.69%
3Y Avg
13.35%
5Y Avg
14.10%
Market Cap
$10.87B
EBITDA Margin
19.03%
TTM Avg
19.69%
3Y Avg
15.98%
5Y Avg
11.44%
Market Cap
$10.54B
EBITDA Margin
-10.43%
TTM Avg
-17.56%
3Y Avg
-24.27%
5Y Avg
-20.72%
Market Cap
$10.97B
EBITDA Margin
27.02%
TTM Avg
27.38%
3Y Avg
26.41%
5Y Avg
26.36%
Market Cap
$10.35B
EBITDA Margin
20.41%
TTM Avg
18.54%
3Y Avg
20.94%
5Y Avg
21.85%
Market Cap
$10.35B
EBITDA Margin
-212.29%
TTM Avg
-1213.73%
3Y Avg
-49114.16%
5Y Avg
-44116.26%
Market Cap
$10.14B
EBITDA Margin
19.75%
TTM Avg
19.29%
3Y Avg
19.87%
5Y Avg
21.06%
Market Cap
$10.13B
EBITDA Margin
2.15%
TTM Avg
3.41%
3Y Avg
4.20%
5Y Avg
4.49%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Twist Bioscience Corporation (TWST) | $10.72B | -29.58% | -25.86% | -40.51% | -66.41% |
| Universal Health Services, Inc. (UHS)vs › | $10.69B | 15.05% | 14.69% | 13.35% | 14.10% |
| BioMarin Pharmaceutical Inc. (BMRN)vs › | $10.87B | 19.03% | 19.69% | 15.98% | 11.44% |
| 10x Genomics, Inc. (TXG)vs › | $10.54B | -10.43% | -17.56% | -24.27% | -20.72% |
| The Cooper Companies, Inc. (COO)vs › | $10.97B | 27.02% | 27.38% | 26.41% | 26.36% |
| Globus Medical, Inc. (GMED)vs › | $10.35B | 20.41% | 18.54% | 20.94% | 21.85% |
| ImmunityBio, Inc. (IBRX)vs › | $10.35B | -212.29% | -1213.73% | -49114.16% | -44116.26% |
| Align Technology, Inc. (ALGN)vs › | $10.14B | 19.75% | 19.29% | 19.87% | 21.06% |
| Molina Healthcare, Inc. (MOH)vs › | $10.13B | 2.15% | 3.41% | 4.20% | 4.49% |
| Bio-Techne Corporation (TECH)vs › | $11.34B | 28.74% | 23.07% | 27.33% | 30.04% |
Gross Margin
52.0%
EBITDA Margin
-29.6%
Operating Margin
-31.9%
Net Margin
-31.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -24.92% |
| 2026-03-31 | -29.12% |
| 2025-12-31 | -25.75% |
| 2025-09-30 | -24.17% |
| 2025-06-30 | -25.32% |
| 2025-03-31 | -37.89% |
| 2024-12-31 | -31.86% |
| 2024-09-30 | -34.69% |
| 2024-06-30 | -98.97% |
| 2024-03-31 | -53.90% |
| 2023-12-31 | -54.28% |
| 2023-09-30 | -62.16% |
| 2023-06-30 | -82.04% |
| 2023-03-31 | -90.74% |
| 2022-12-31 | -72.52% |
| 2022-09-30 | -90.60% |
| 2022-06-30 | -101.08% |
| 2022-03-31 | -118.09% |
| 2021-12-31 | -125.64% |
| 2021-09-30 | -98.50% |
| 2021-06-30 | -112.44% |
| 2021-03-31 | -113.90% |
| 2020-12-31 | -108.95% |
| 2020-09-30 | -68.07% |
| 2020-06-30 | -124.83% |
| 2020-03-31 | -158.20% |
| 2019-12-31 | -316.51% |
| 2019-09-30 | -191.15% |
| 2019-06-30 | -195.10% |
| 2019-03-31 | -182.19% |
| 2018-12-31 | -186.43% |
| 2018-09-30 | -218.57% |
| 2018-06-30 | -241.39% |
| 2018-03-31 | -246.56% |
| 2017-12-31 | -358.57% |
| 2017-09-30 | -443.62% |
| 2017-06-30 | -408.75% |
